A review by the European Court of Auditors of the management of conflicts of interests in four independent agencies of the European Union found that the European Medicines Agency has some of the most advanced policies and procedures for declaring, assessing and managing potential conflicts of interests in place.
The report, which is based on policies and rules in place a year ago when the Court began its work, also makes a number of recommendations, many of which have already been implemented but noting that there is some scope for further improvements.
Guido Rasi, the EMA's executive director, said that the Agency "is committed to continuous review and improvement of its handling of conflicts of interests. We will look carefully at the recommendations of the Court, together with the European Commission, the other EU agencies and our national counterparts in the European medicines network."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze